TITLE

Avastin Gets FDA Vote of Confidence

PUB. DATE
May 2009
SOURCE
Pharmaceutical Representative;May2009, Vol. 39 Issue 5, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the recommendation given by the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee for Genentech Inc.'s Avastin. The committee recommended Avastin, bevacizumab drug, for the treatment of patients with glioblastoma. David Schenkein, senior vice president of Genentech's Clinical Hematology and Oncology, expects to work with the FDA for their next drugs to provide treatment to people with glioblastoma.
ACCESSION #
39258119

 

Related Articles

  • FDA Splits with ODAC, OKs Avastin Use in Breast Cancer. Morrison, Trista // BioWorld Today;2/25/2008, Vol. 19 Issue 37, p1 

    The article reports on the split decision between the U.S. Food and Drug Administration (FDA) and Oncologic Drugs Advisory Committee (ODAC) over the new breast cancer drug, Avastin by Genentech Inc. It is inferred that the approval by FDA of the drug could translate to double revenue for the...

  • Genentech Provides Update from FDA Hearing on Avastin for Metastatic Breast Cancer.  // Biomedical Market Newsletter;7/5/2011, p315 

    The article focuses on the update from the U.S. Food and Drug Administration (FDA) hearing provided by Genentech Inc. on the use of avastin for metastatic breast cancer. Global Product Development chief medical officer Hal Barron says his disappointment towards the recommendation of FDA's...

  • FDA Questions Avastin's Effect, Safety in Breast Cancer. Young, Donna // BioWorld Today;7/19/2010, Vol. 21 Issue 137, p1 

    The article reports on the questions raised by the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) regulators on the safety of Avastin or bevacizumab use for treating HER2-negative breast cancer. The drug is being marketed by Genentech and its parent company...

  • FDA Panel: Revoke Avastin's Approval in Breast Cancer. Young, Donna // BioWorld Today;7/21/2010, Vol. 21 Issue 139, p1 

    This article reports on the revocation by the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) of Avastin's approval in the U.S. as a treatment for HER2-negative metastatic breast cancer. According to the FDA panel, both Genentech Inc. and its parent firm Roche AG...

  • FDA Pushes Trial Repeat For NeoPharm's GBM Drug.  // Bioworld Week;4/2/2007, Vol. 15 Issue 14, p5 

    The article reports that the U.S. Food and Drug Administration's Office of Oncology has required another Phase III trial of NeoPharm Inc.'s lead drug, cintredekin besudotox, in Waukegan, Illinois. The agency wants the trial before considering an application for its acceptance in the treatment of...

  • ODAC recommends the removal of breast cancer indication from bevacizumab label. Harris, Jason // Hem/Onc Today;8/10/2010, Vol. 11 Issue 15, p1 

    The article reports on the recommendation by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) in August 2010 to eliminate bevacizumab's indication as a first-line therapy for metastatic breast cancer.

  • Breast cancer indication for bevacizumab. Elliot, William T. // Infectious Disease Alert;Sep2010 Supplement, p2 

    The article reports on the recommendation of the Oncologic Drugs Advisory Committee of the U.S. Food and Drugs Administration (FDA) to remove the indication for breast cancer treatment for bevacizumab, brand name Avastin.

  • Breast cancer indication for bevacizumab. Elliott, William T. // Alternative Medicine Alert;Sep2010 Supplement, p2 

    The article reports on the recommendation by the Oncologic Drugs Advisory committee of the U.S. Food and Drug Administration (FDA) for the removal of the indication for breast cancer treatment for bevacizumab (Avastin) as it provided no survival benefit in combination with docetaxel and...

  • Avastin gets thumbs down from FDA advisors.  // Reactions Weekly;7/31/2010, Issue 1312, p6 

    The article reports on the opposition of the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) to the use of bevacizumab in combination with paclitaxel for first-line treatment of advanced HER2-negative breast cancer.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics